PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex

Fabozzi, Scott J.; Kolm, Paul; Schellhammer, Paul F.

doi:10.1016/1078-1439(95)00011-6

Cited by 5 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With 150 mg bicalutamide daily in a sequential version replacing flutamide in the MAB, the results were in the same range [68,69] . Even 50 mg/day bicalutamide given at the time of progression after gonadal androgen deprivation was followed by 1 50% PSA declines in 14/28 and 10/32 men respectively [70,71] .…”

Section: Non-traditional Approachesmentioning

confidence: 99%

Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation

2007

View full text Add to dashboard Cite

Objective: To evaluate systematically the current endocrine treatment options for patients with biochemical recurrence after radical prostatectomy or radiation therapy for localized prostate cancer. Methods: Literature search of PubMed documented publications and abstracts from international meetings. Key items included timing and type of salvage hormone therapy, length of its application and handling of side effects. Results: The majority of patients with isolated prostate-specific antigen (PSA) relapse are not candidates for salvage treatment with curative intent. The PSA threshold that triggers initiation of hormonal therapy is debatable and should be based also on pretreatment risk assessment. Intermittent androgen suppression is an emerging concept to circumvent the unresolved controversy of early versus deferred endocrine therapy. Since the tumor load at time of recurrence is low, peripheral androgen blockade with an antiandrogen and a 5α-reductase inhibitor is an acceptable first choice. In case of progression, addition of a LHRH analogue would be the next step. Antiandrogen withdrawal and second-line antiandrogens are clinically of limited value. Conclusions: Biochemical-only progression after definitive treatment in curative intent is different from objective or even symptomatic relapse and allows for sequential hormonal therapy with a variety of compounds.

show abstract

Section: Non-traditional Approachesmentioning

confidence: 99%

Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation

2007

View full text Add to dashboard Cite

show abstract

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

Scher¹,

Liebertz²,

Kelly³

et al. 1997

JCO

200

View full text Add to dashboard Cite

Classifying patient tumors on the basis of prior hormone exposure permits a more precise estimate of the potential benefit of a specific hormone therapy for the individual patient. The precision is further increased by reporting the effects of a drug on each parameter of disease independently. The difference in outcomes for patients with androgen-independent progression suggests that the specific hormone therapy administered and the response to that therapy can influence the biology of the relapsing tumor and the sensitivity to subsequent therapies. The sensitivity to bicalutamide after progression on flutamide deserves further study.

show abstract

An update on bicalutamide in the treatment of prostate cancer

Schellhammer¹

1999

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

In this update, bicalutamide (Casodex, Zeneca Pharmaceuticals) has been confirmed as an effective, well-tolerated and convenient non-steroidal anti-androgen for advanced prostate cancer. Preclinical and clinical studies have indicated its potential as monotherapy, with quality of life advantages compared with castration. A head-to-head comparison with flutamide, where both anti-androgens were used as part of combined androgen blockade, has suggested that the choice of components in this regimen can influence outcome, and has demonstrated that bicalutamide is better tolerated than flutamide. There is also preliminary evidence to support the potential use of bicalutamide in treatment of early-stage disease and tumours that are refractory to other non-steroidal anti-androgens.

show abstract

PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex

Cited by 5 publications

References 17 publications

Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation

Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

An update on bicalutamide in the treatment of prostate cancer

Contact Info

Product

Resources

About